Article Collection

Special themed collection: The changing face of migraine

Editors: Messoud Ashina, Lars Edvinsson, Paolo Martelletti The Journal of Headache and Pain.

Migraine management has long relied on medication developed to treat other conditions. However, the emergence of a new class of preventative drugs is now within our grasp. Targeted prophylactic migraine treatment is becoming a reality and the neuropeptide calcitonin gene-related peptide (CGRP) plays a central role in this breakthrough.

This topical collection explores the changing face of migraine and examines where we are in meeting the long-standing unmet need for a more individualized and targeted approach.


Review articles



The APCs (article processing charges) for the articles in this thematic series ‘The changing face of migraine’ were made possible through independent educational sponsorship by Eli Lilly and Company. Eli Lilly and Company provided the funds through an educational grant which included enduring materials within the context of a symposium at the 12th European Headache Federation Congress in September 2018, chaired by Paolo Martelletti. This grant was provided to Springer Healthcare IME who organized the symposium and all of the enduring materials. Three of the articles in this thematic series were developed from content presented at the symposium.  Eli Lilly and Company were not involved in the planning of the thematic series, the selection process for topics, nor in any peer review or decision-making processes.

The articles have undergone the journal’s standard peer review process overseen by the Editor-in-Chief.  For articles where the Editor-in-Chief is an author, the peer review process was overseen by one of the other Editors responsible for this thematic series.

The costs for printing and distributing the thematic collection were covered within the educational grant provided by Eli Lilly and Company.